Relay Therapeutics, Inc. Common Stock (RLAY) Stock
Key stats
- Market cap
- $4.36B
- Price / Earnings ratio
- -15.0x
- EPS (TTM)
- -$1.50
- Volume
- Loading
- 52-week high
- $21.27
- 52-week low
- $5.95
Source: third-party data provider, as of November 13, 2026
Compare with RLAY
Recent news

Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
RLAY

Relay Therapeutics CFO Sells 17,717 Shares for $350,000
Relay Therapeutics CFO Sells 17,717 Shares for $350,000
RLAY

4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma
RLAY

Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates
Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates
RLAY
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 56.92
- MACD 12/26/9
- 0.29
- EMA 9 of MACD
- 0.08
- MACD histogram
- 0.22
- SMA 50
- $18.40
- Price above SMA 50
- EMA 50
- $18.44
- Price above EMA 50
- SMA 200
- $15.43
- Price above SMA 200
- EMA 200
- $14.98
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
Large biopharma companies looking at China assets right now, says Goldman Sachs Salveen Richter
RLAY

Relay Therapeutics CFO Sells 17,717 Shares for $350,000
Relay Therapeutics CFO Sells 17,717 Shares for $350,000
RLAY

4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma
4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma
RLAY

Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates
Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates
RLAY

Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Should You Buy?
Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Should You Buy?
RLAY

Relay Therapeutics Insider Sale Tops $3 Million as Shares Surge 500% This Past Year
Relay Therapeutics Insider Sale Tops $3 Million as Shares Surge 500% This Past Year
RLAY

Is Relay Therapeutics a Buy After Promising Trial Results?
Is Relay Therapeutics a Buy After Promising Trial Results?
RLAY

Why Relay Therapeutics Stock Popped on Wednesday
Why Relay Therapeutics Stock Popped on Wednesday
RLAY

Relay's treatment shown to shrink vascular malformations in mid-stage trial
Relay's treatment shown to shrink vascular malformations in mid-stage trial
RLAY

This Biotech's Drug Just Wiped The Floor With Forecasts
This Biotech's Drug Just Wiped The Floor With Forecasts
RLAY
News tone: automated (AI) classification of the article's content, not a price prediction.
About Relay Therapeutics, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Sanjiv K. Patel M.A., M.B.A., M.D., MBBS | CEO, President & Director | 1974 |
| Mr. Thomas Catinazzo | Chief Financial Officer | 1976 |
| Dr. Mark Murcko Ph.D. | Founder & Independent Director | 1960 |
| Mr. Peter Rahmer | Chief Corporate Development Officer | 1982 |
| Dr. Donald A. Bergstrom M.D., Ph.D. | President of Research & Development | 1972 |
| Ms. Dorothee Kern Ph.D. | Founder | — |
| Dr. David Elliot Shaw Ph.D. | Founder | 1951 |
| Dr. Matthew P. Jacobson Ph.D. | Founder | — |
| Mr. Jim Watters Ph.D. | Chief Scientific Officer | — |
| Ms. Soo-Yeun Lim J.D. | Senior VP & General Counsel | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 56.92
- MACD 12/26/9
- 0.29
- EMA 9 of MACD
- 0.08
- MACD histogram
- 0.22
- SMA 50
- $18.40
- Price above SMA 50
- EMA 50
- $18.44
- Price above EMA 50
- SMA 200
- $15.43
- Price above SMA 200
- EMA 200
- $14.98
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
3 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $29.00
- Average
- $30.33
- High
- $31.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -16.7 | +7.2 | ||||||||||
| 2022 | -31.6 | +4.4 | +24.4 | -24.7 | -34.2 | +3.8 | +5.1 | +27.1 | -10.2 | -0.4 | -17.3 | -16.0 |
| 2023 | +42.7 | -25.5 | +2.0 | -32.7 | -2.6 | +13.6 | -0.5 | -14.2 | -23.8 | -18.9 | +15.8 | +26.6 |
| 2024 | -22.0 | +10.0 | -17.7 | -18.7 | -3.8 | -4.0 | +28.4 | -15.0 | +9.4 | -13.9 | -19.5 | -11.8 |
| 2025 | +4.0 | -23.7 | -18.1 | +34.8 | -8.8 | +8.8 | +0.0 | +6.8 | +42.6 | +34.2 | +14.1 | +14.3 |
| 2026 | -6.4 | +25.9 | +1.6 | +20.3 | +10.5 | +31.2 | +6.0 | -2.1 | -2.4 | -0.8 | +14.1 |



